Tango Therapeutics
TNGX
77 hedge funds and large institutions have $319M invested in Tango Therapeutics in 2022 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 27 increasing their positions, 10 reducing their positions, and 21 closing their positions.
170% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 10
24% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 21
7% more funds holding
Funds holding: 72 → 77 (+5)
0.56% more ownership
Funds ownership: 79.59% → 80.15% (+0.56%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
40% less capital invested
Capital invested by funds: $528M → $319M (-$209M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.1M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$9.32M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.58M |
| 4 |
Bessemer Group
Woodbridge,
New Jersey
|
+$4.29M |
| 5 |
SCA
Southpoint Capital Advisors
New York
|
+$4.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$17.1M |
| 2 |
CC
Casdin Capital
New York
|
-$12M |
| 3 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$6.69M |
| 4 |
Janus Henderson Group
London,
|
-$4.44M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.52M |
TNGX Hedge Fund Activity: Q2 2022 in Review
77 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Tango Therapeutics (TNGX) for Q2 2022, worth a combined $319M — down 40% from $528M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new TNGX positions and 21 closed out — a net gain of 5 holders — while 27 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock, adding an estimated $10.1M. The largest seller was RA Capital Management, exiting entirely with an estimated $17.1M sold.
- 77 institutional investors held Tango Therapeutics (TNGX) as of Q2 2022, up from 72 in Q1 2022.
- Funds reported $319M of Tango Therapeutics stock for Q2 2022, down 40% quarter-over-quarter.
- 26 funds opened new Tango Therapeutics positions in Q2 2022 and 21 closed out, a net change of +5 holders.
- The largest Tango Therapeutics buyer in Q2 2022 was BlackRock, an estimated $10.1M added.
- The largest Tango Therapeutics seller in Q2 2022 was RA Capital Management, an estimated $17.1M sold.
Based on aggregated 13F filings for Q2 2022.